Evidence map›Paper›PMID 8799169›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America1996

Activation of Jak/STAT proteins involved in signal transduction pathway mediated by receptor for interleukin 2 in malignant T lymphocytes derived from cutaneous anaplastic large T-cell lymphoma and Sezary syndrome.

Q Zhang, I Nowak, E C Vonderheid, A H Rook, M E Kadin, P C Nowell, L M Shaw, M A Wasik

Registry-linked trialOpen access · greenAbstract readComparative Study
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 1996. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07781449 (An Investigator-Initiated, Descriptive, Proof-of-Concept, Open-Label Pilot Study Focusing on Topical JAK Inhibition as a Novel Treatment of Cutaneous T-Cell Lymphoma), which is not on this map. Cited by 87 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
87citing papers in PubMed, 1 pooled it
20.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07781449 phase2not yet recruitingnot on this mapstarted 2026, after this paper: background citation

An Investigator-Initiated, Descriptive, Proof-of-Concept, Open-Label Pilot Study Focusing on Topical JAK Inhibition as a Novel Treatment of Cutaneous T-Cell Lymphoma

TypeinterventionalSponsorAarhus University HospitalRan2026 to 2030Enrolled15ConditionsMycosis Fungoides, Cutaneous T-cell LymphomaArmsdelgocitinib
3 · Its place in the literature

Who cites it

87 citing papers in PubMed, 1 synthesis or guideline pooled it, 226 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. NewCells · 2023
    Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Review

27 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Q ZhangDepartment of Pathology, University of Pennsylvania Medical Center, Philadelphia 19104, USA.
I Nowak
E C Vonderheid
A H Rook
M E Kadin
P C Nowell
L M Shaw
M A Wasik
University of Pennsylvania · US

Funding

STUDIES OF NEOPLASTIC AND NORMAL LEUKOCYTESR35CA042232 · NCI · UNIVERSITY OF PENNSYLVANIA · PI NOWELL, PETER C · 1986 to 1999
–
NCI NIH HHS CA-42232
6 · The paper itself

Abstract

Signaling through the interleukin 2 receptor (IL-2R) involves phosphorylation of several proteins including Jak3, STAT5, and, in preactivated cells, STAT3. In the present study, we examined the functional status of the IL-2R-associated Jak/STAT pathway in malignant T lymphocytes from advanced skin-based lymphomas: anaplastic large T-cell lymphoma (ALCL) and Sezary syndrome (SzS). Proliferation of three ALCL cell lines (PB-1, 2A, and 2B) was partially inhibited by rapamycin, a blocker of some of the signals mediated by IL-2R, but not by cyclosporin A, FK-506, and prednisone, which suppress signals mediated by the T-cell receptor. All the cell lines expressed on their surface the high-affinity IL-2R (alpha, beta, and gamma c chains). They showed basal, constitutive phosphorylation, and coassociation of Jak3, STAT5, and STAT3. Weak basal phosphorylation of IL-2R gamma c was also detected. In regard to SzS, peripheral blood mononuclear cells from 10 of 14 patients showed basal phosphorylation of Jak3, accompanied by phosphorylation of STAT5 in 9 patients, and STAT3 in 4 patients. However, in vitro overnight culture of SzS cells without exogenous cytokines resulted in markedly decreased Jak3 and STAT5 phosphorylation, which could be reversed by stimulation with IL-2. This indicates that the basal phosphorylation of Jak3 and STAT5 in freshly isolated SzS cells is induced rather than constitutive. The basal activation of the Jak/STAT pathway involved in IL-2R signal transduction in ALCL and SzS cells reported here suggests that this pathway may play a role in the pathogenesis of cutaneous T-cell lymphomas, although the mechanism (induced versus constitutive) may vary between different lymphoma types.

Indexed as

Lymphocyte ActivationMilk ProteinsCell MembraneCyclosporineDNA-Binding ProteinsHumansImmunosuppressive AgentsJanus Kinase 3Lymphoma, T-Cell, CutaneousPhosphorylationPolyenesPrednisoneProtein BindingProtein-Tyrosine KinasesReceptors, Interleukin-2Sezary SyndromeCyclosporineDNA-Binding ProteinsImmunosuppressive AgentsJAK3 protein, humanJanus Kinase 3Milk ProteinsPolyenesPrednisoneProtein-Tyrosine KinasesReceptors, Interleukin-2SirolimusSTAT3 protein, humanSTAT3 Transcription FactorSTAT5 Transcription FactorTacrolimusTrans-Activators

Identifiers

PMID8799169
PMCPMC38610
OpenAlexW2081003617

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.